New combo tackles relapsed blood cancers after transplant
NCT ID NCT05226455
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of two drugs (venetoclax and azacitidine) plus donor immune cells in 55 adults with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that returned after a stem cell transplant. The goal is to find the best dose and see if the treatment can improve outcomes. The study is active but no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
venetoclax (Venclyxto) and azacitidine (Vidaza) with or without donor lymphocyte infusion
What this could lead to
If successful, this combination could offer a new treatment option for patients whose MDS or AML returns after a stem cell transplant.
What could go wrong
This is an early phase I-II study with only 55 participants, so results are preliminary. The drugs can cause serious side effects, and the donor cells may attack the patient's body (graft-versus-host disease).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MDS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Hôtel Dieu
Nantes, 44093, France
-
CHU d'Angers
Angers, 49933, France
-
CHU de Grenoble
Grenoble, 38043, France
-
CHU de Haut-Lévèque
Pessac, 33604, France
-
Centre Henri Becquerel
Rouen, 76038, France
-
Centre Hospitalier Lyon-Sud
Pierre-Bénite, 69495, France
-
Hôpital Dupuytren
Limoges, 87042, France
-
Hôpital Saint louis
Paris, 75010, France
-
Hôpital Saint-Eloi
Montpellier, 34295, France
-
Hôpital l'Archet I
Nice, 06200, France
-
IUCT Oncopole
Toulouse, 31059, France